Sarepta Therapeutics buy tamam
Start price
09.01.18
/
50%
€48.59
Target price
04.11.21
€153.34
Performance (%)
57.44%
End price
05.11.21
€76.50
Summary
This prediction ended on 05.11.21 with a price of €76.50. With a performance of 57.44% the BUY prediction by tamam was a big success. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Sarepta Therapeutics | -5.062% | -5.062% | -84.983% | -84.566% |
| iShares Core DAX® | -1.212% | 1.925% | 17.589% | 68.786% |
| iShares Nasdaq 100 | -4.714% | -1.810% | 0.450% | 100.066% |
| iShares Nikkei 225® | -2.976% | -2.660% | 10.156% | 43.024% |
| iShares S&P 500 | -2.744% | -0.448% | 0.320% | 63.222% |
Comments by tamam for this prediction
In the thread Sarepta Therapeutics diskutieren
Sarepta continues to be a core buy in biotech
In today´s investor update management guided for fourth quarter revenue of $57.3 million and full year 2018 Exondys 51 revenue in the range of $295 million to $305 million (roughly double that of 2017).
tamam stimmt am 09.01.2018 der Outperform-Einschätzung der institutionellen Analysten zu.
In the thread Trading Sarepta Therapeutics
Die von tamam gewählte maximale Laufzeit wurde überschritten